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The Promise and Peril of the Genomic 
Revolution
Francis S. Collins
Edited Transcript of the 2008 Inamori Ethics Prize Speech
On this occasion, I thought it would be appropriate to talk about the science 
of the human genome and some of the ethical challenges it has placed in 
front of us. Many of these challenges are in the process of being addressed, but 
we are far from done. Because science keeps changing, the ethical challenges 
that demand our attention are constantly evolving as well. 
The title of my lecture may sound dramatic, but we are living in dramatic 
times. The reading of our own DNA instruction book, the human genome, 
is leading to unprecedented revelations about human biology that promise 
to transform medicine in a way that has not happened since the introduction 
of antibiotics. However, this transformation will not happen overnight. So 
far, studies of the human genome have had a direct impact on the medical 
care of only a few people. For most of us, the moment of genomic informa-
tion shaping our own medical future has not quite arrived. Still, I envision 
it coming pretty quickly, and, in fact, that is where I see both the promise 
and peril of genomics residing. 
Before we look to the future, let us briefly consider the past. We went from 
having the structure of DNA deduced in April 1953 to just fifty years later, 
in April 2003, the successful completion of the Human Genome Project, 
ahead of schedule and under budget. The United States had the privilege of 
taking the lead in this historic endeavor, but it was very much an international 
project that included a substantial contribution from our friends and col-
leagues in Japan, as well as in China, United Kingdom, France, and Germany. 
We shared goals that were well articulated, we stood up for immediate data 
release, and we maintained data quality standards of the highest possible level. 
All of these folks selflessly worked together to make this happen because 
they believed in the promise of this project: to transform our understanding 
of human biology and medicine. 
It was great that the Human Genome Project built us a reference sequence 
of the human genome, a foundation for understanding the part of the genome 
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that we all share. But what about that small fraction of the genome—about 
0.5%—that varies from individual to individual? We needed more tools to 
explore that variable part and how those genetic variants interact with the 
environment to influence our risk of heart disease, diabetes, cancer, and other 
common diseases. 
So, we pulled together another international consortium involving nearly 
two thousand scientists to produce a catalog of human variation, dubbed 
the Haplotype Map (HapMap). This effort has enabled investigators who 
are trying to identify genetic risk factors for common diseases to conduct 
systematic, genome-wide association studies (GWAS), a far more efficient 
process than the previous approach (known as the candidate gene strategy). 
The first among many GWAS successes came in 2005 with the identification 
of a gene, called complement factor H, for age-related macular degeneration, 
a common cause of blindness in the elderly. The discovery was a complete 
surprise because complement factor H was not on anybody’s list of candidate 
genes. However, it has led to a revolution of our understanding of that disease 
and a host of ideas about prevention and treatment. 
Another project that builds upon the foundation laid by the Human 
Genome Project is the Cancer Genome Atlas. This project aims to look at 
the genetic mutations involved in many common types of cancer and to do 
so in a very systematic, comprehensive way. This is the leading edge of what 
is going to be an outpouring of new genomic information about cancer in 
the next few years.
What impact will all of this have on medicine? One opportunity will be 
to use genomic information to predict who is at risk for what disease, even 
while they are still healthy. But if I could give you the opportunity to find 
out your risk factors for a dozen common diseases over the next few decades 
at a reasonably accurate level, would you really want that information? I 
think many people would say, “Is there something I could do about it? If 
there isn’t, please spare me.” This means we need to think about how we 
can pair genome-based diagnostics with preventive medicine strategies. In 
some instances, such as inherited forms of colon cancer that can be prevented 
by regular colonoscopy and polyp removal in high risk individuals, we are 
already there. In others, such as people at high risk for inherited forms of 
Alzheimer’s disease, we still have a long way to go.
Another clinical area that is quite exciting is called pharmacogenomics. 
When you are given a drug for a particular condition, sometimes it works 
pretty well. Sometimes you do not seem to get the benefit. Sometimes 
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maybe you get a side effect. What is that all about? We are all different, and 
our responses to drugs are different. So, if you give a group of patients with 
the same diagnosis the same drug, a lot of them will do well, but some will 
get no response or a toxic effect. We should be able to predict that ahead of 
time for a lot of drugs as we get smarter about what is in the genome. 
Ultimately, though, I think the main promise of understanding the genome 
is that it will allow us to identify the targets for therapy that are much closer 
to the action than what we currently know about. You cannot expect these 
kinds of promises to come true without very strong support for biomedical 
research in the coming years, but the promise has never been greater than 
it is today. 
Those are just a few of the things that those of us working in this field are 
excited about in terms of genomics’ transforming capabilities for medicine. 
But what about the possible ethical, legal, and social implications (ELSI) 
of such newfound knowledge and abilities? One of the things that makes 
me the most proud about the Human Genome Project is that it took ELSI 
concerns seriously from the very beginning. In fact, it has been estimated 
that the research support for ELSI in the genome arena is the largest amount 
of money that has ever been spent on bioethics research. We have created an 
environment in which bioethics is not shoved off in a corner, or considered 
something to think about later; it is part and parcel of this genomics revolution. 
Let me mention a few of the many complex ELSI issues facing the field 
of genomics. To begin with, we cannot discount the fact that the field of 
human genetics got off to a very bad start in the early twentieth century 
with its focus on eugenics. We must not forget the lessons of the past, and 
be constantly on guard for the kind of misunderstanding and misapplica-
tion of genetics that can have horrendous consequences. We also need to be 
cognizant of how our expanding knowledge of human genetic variation may 
play into issues of race and ethnicity. Historian Evelyn Brooks Higginbotham 
once said that everyone talks about race as if they know what it is, but if 
you ask someone to define what they mean by race, they will arrive almost 
immediately at confusion. Yes, race is connected in some way with ancestral 
geographic origins, but it may also carry with it history, cultural practices, 
socioeconomic status, environmental exposures, and even stress. So, when you 
see that a particular disorder seems to be more frequent in one racial group 
than another, for example, diabetes in Pima Indians, you should not rush 
to the conclusion that the answer is genetic. In most cases, when the dust 
settles, I think we will learn that health disparities are enormously complex.
3
Collins: 2008 Inamori Ethics Prize Speech: The Promise and Peril of the Ge
Published by Case Western Reserve University School of Law Scholarly Commons, 2012
The International Journal of Ethical Leadership   Fall 2012 10
Another very complex, but quite different, ELSI concern is intellectual 
property. I am very proud of the fact that in 1996, when the international 
sequencing leaders met for the first time as a group, we had a frank discus-
sion about this issue. On the whiteboard during that meeting, we set forth 
this bold goal: “Aim to have all sequence freely available and in the public 
domain for both research and development in order to maximize its benefit 
to society.” Now, that was a moment, a moment where a group of scientific 
leaders, without necessarily having the approval of all the authorities in their 
respective countries, but in the spirit of doing the right thing, made a deci-
sion to change the ethics of data release in a profound way, not waiting for 
publication, not waiting for anything, releasing the data every twenty-four 
hours. That attitude of immediate data release has now extended well beyond 
that decision twelve years ago into many other areas of biomedical research, 
providing great benefit to the public because of the way it accelerates the 
discoveries that need to happen and levels the playing field, giving anybody 
with a good idea the chance to start working right away. 
Genetic discrimination was another ELSI issue identified right from the 
beginning as particularly important. We knew that if we did not fix this, 
people were going to be afraid to find out about their own DNA because 
they would be discriminated against by losing their health insurance or their 
jobs. Should that be used to take away your access to health care, or to a job 
for which you are otherwise well-qualified? No, that is unjust, and, frankly, 
puts all of us at risk. If you came here thinking you were the perfect genetic 
specimen, I have really bad news for you. There are not any—each of us has 
a few dozen genetic glitches that increase our risks for particular diseases.
Clearly, we needed to do something about the genetic discrimination 
issue. In 1990, the Americans with Disabilities Act was passed and that had 
some potential of being helpful. States began to take action on this issue in 
the 1990s, and in 1995, Louise Slaughter, a Democratic representative from 
New York, introduced the first federal legislation about genetic discrimina-
tion, HR 2748. In 1996, Congress passed the Health Insurance Portability 
and Accountability Act, which included genetic information on the list of 
things that cannot be used to take away your health insurance if you are 
in a group plan. But that act did not say anything about individual health 
plans, and, obviously, none of us know if we might need an individual plan 
at some future point. Time went on, with bills being introduced in Congress 
every other year and going nowhere. In 2000, President Clinton issued an 
executive order that protected federal employees from genetic discrimination, 
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but more was still needed. Happily, this story has a good ending. On May 1, 
2008, the bill, now called the Genetic Information Nondiscrimination Act 
(GINA), cleared Congress and President George W. Bush signed the bill into 
law twenty days later. 
We now finally are in a circumstance in this country where one need not 
fear that the genetic information will be used for discriminatory purposes in 
health insurance or in the workplace. But that most certainly does not solve all 
our problems. What about genetic testing? Is it subject to sufficient oversight? 
Can you be sure, if somebody is trying to get you to take a genetic test, that 
the results are trustworthy? And, of course, that becomes of particular interest 
right now because there are companies out there marketing genome-wide 
analysis directly to the public. The science behind these efforts is pretty good, 
but the problem is we do not know very much about the interventions that 
someone might want to consider if found to be at high risk. We can guess 
at them, but it would be nice if we actually knew what would be beneficial. 
Are we jumping the gun here? Also, if health care providers were involved 
in these kinds of interchanges, would your doctor or your nurse be able to 
tell you what this information meant? Not necessarily. Most health care 
professionals have had no training in genetics; they are also struggling to 
make sense of this. 
And what about using genomics as a tool to enhance human traits? Many 
people are particularly worried about that. They are fine with using genomics 
to cure cancer, but do not approve of genomic tinkering aimed at making the 
next generation smarter or more athletic. Currently, most of the scenarios for 
enhancement are totally unrealistic. Researchers will not be in a circumstance 
to modify the DNA that gets passed from parent to child in humans anytime 
in the foreseeable future. Even if they could, it would be unethical because 
we really would not know the consequences for generations to come—and 
that will not pass muster with any ethicists that I know. 
Finally, we need to ask ourselves whether, in our enthusiasm for scientific 
progress, we may be ascribing to DNA properties that it does not really 
deserve. Are we increasingly thinking of ourselves as hardwired by our DNA 
and, as such, beginning to neglect many other vital aspects of what it means 
to be human, such as parenting, education, and spirituality? That would be a 
profound misunderstanding of the science. Even when we have completely 
understood the human genome, we will not understand free will. May it 
always be that, as we venture deeper into science, we hold even firmer to 
our humanity.
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